

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,025,964 B1
APPLICATION NO. : 09/308027
DATED : April 11, 2006
INVENTOR(S) : Akinori Kume et al.

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page, Item 56 References Cited Section - OTHER PUBLICATIONS, line 4: "Janpanese" should be --Japanese--.

On the Title Page, Item 57

In the Abstract, lines 1-3: "A peptide-based immunotherapeutic agent effective for every allergy patient is provided. A reagent for typing HLA class II molecules of the patient to be used in selecting a peptide-based immunotherapeutic agent effective for every allergy patient is also provided."

should read as follows:

--Peptide-based immunotherapeutic agents effective for each individual allergy patient are provided. Reagents for typing HLA class II molecules of patients to be used in selecting peptide-based immunotherapeutic agents effective for each individual allergy patient are also provided.--.

Col. 5, second paragraph, line 16, "challenge" should be --challenged--.

Col. 6, line 6, "to" should be --of--.

Col. 6, line 7, "allergy" should be--allergy.--.

Col. 6, line 7, "caused by antigen peptides presented by HLA-DPB1*0501. HLA-DPB1*0501 is frequently present in patients suffering from Cryptomeria pollen allergy induced by Cry j 1 and Cry j 2, and antigen peptides presented by different HLA class II molecules (DR.DQ or DP) (Japanese Patent Application No. Hei 8-70702)."

should read as follows:

--These multiple-epitope peptides comprise antigen peptides presented by different HLA class II molecules (DR, DQ or DP),and antigen peptides that are derived from both Cry j 1 and Cry j 2 and which are presented by HLA-DPB1*0501 (Japanese Patent Application No. Hei 8-80702). HLA-DPB1*0501 exists at a high frequency in patients suffering from cryptomeria pollen allergy.--

Col. 6, line 4, after "provided" please add --, for example,--.

Col. 6, line 5, "multiple" should be --multi--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,025,964 B1
APPLICATION NO. : 09/308027
DATED : April 11, 2006
INVENTOR(S) : Akinori Kume et al.

Page 2 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 7, line 1, "there is a bias in the use of HLA class II (at the locus level) molecules that is determined by the antigen."

should read as follows:

--, depending on the antigen type, there is a bias towards restriction molecules at the HLA class II locus level, and that this defines immune reactions.--.

Col. 8, line 11, "Moreover, if T-cell response can be found in a subject (an allergic-response-positive patient), the type of the subject's HLA class II molecules restricting the antigen peptides that induced the T-cell response can be identified as the HLA class II type endowing susceptibility to said allergen in the subject."

should read as follows:

--For subjects showing a T cell response (allergy response-positive patients), the type of HLA class II restriction molecule for the antigen peptide that induces the T cell response can be identified as the subjects' HLA class II type.--.

Col. 8, line 65, "expression of a polypeptide with a peptide composed of"
should read as follows: --expressing, as a polypeptide, a peptide with--.

Col. 9, line 14, "shows the overlapping peptides of Cry j 1 containing epitopes recognized by patient's T-cells"

should read as follows: --shows Cry j 1 overlapping peptide sequences and the patients' T-cell epitope sites.--

Col. 9, line 18, "shows the overlapping peptides of Cry j 2 containing epitopes recognized by patient's T-cells"

should read as follows: --shows Cry j 2 overlapping peptides and the patients' T-cell epitope sites.--.

Col. 9, line 39, "shows the immune responses of CB6F1 mouse to Cry j 2 when the antigen peptide p186-200 of Cry j 2 was administered to the mouse."

should read as follows; --shows the immune response of CB6F1 mice to Cry j 2 when the antigen peptide p236-250 of Cry j 2 was administered to the mice.--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,025,964 B1
APPLICATION NO. : 09/308027
DATED : April 11, 2006
INVENTOR(S) : Akinori Kume et al.

Page 3 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 11, line 1, "The number of T-cell epitope sites of Cry j 1 recognized by each patient was 9.8 ± 3.0 on average and ranged from 4 = 15 epitopes."

should read as follows:

--Identification of T-cell epitope sites using T-cell lines recognizing Cry j 1 revealed that the number of T-cell epitope sites recognized by each patient was 9.8 ± 3.0 on average and ranged from 4 = 15 epitopes.--

Col. 12, line 36, "Restriction molecules of each LHA class II type of T-cell clones whose restriction molecules were identified at the locus level can be identified by using, as antigen-presenting cells, mouse L-cells transformed with the DR gene and B-cell lines that are homozygous at the DQ or DP loci."

should read as follows:

--Restriction molecules of each HLA class II type of T-cell clones whose restriction molecules were identified at the locus level can be identified by using as antigen-presenting cells, mouse L-cells transformed with the DR gene and B-cell lines having the same DQ or DP haplotype.--

Col. 13, line 7, "(Medojenics)" should be --(MedGenics)--.

Col. 55, Claim 1, line 48, "0501" should be --1501--.

Col. 56, Claim 2, line 47, "0501" should be --1501--.

This certificate supersedes Certificate of Correction issued December 12, 2006.

and April 3, 2007,

Signed and Sealed this

Third Day of April, 2007

By _____
Assistant Commissioner for Patent and Trademark

Note
Note